Related Experiment Video
Updated: Jul 4, 2026
07:16
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
Cubyl amides: novel P2X7 receptor antagonists
Hendra Gunosewoyo1, Jun Liu Guo, Maxwell R Bennett
1School of Chemistry, University of Sydney, NSW 2006, Australia.
Bioorganic & Medicinal Chemistry Letters
|June 6, 2008
Summary
New polycyclic amides were synthesized and found to be selective antagonists of the P2X7 receptor (P2X7R) in rat microglia. These compounds show potential for targeting neuroinflammation and related conditions.
Area of Science:
- Medicinal Chemistry
- Neuroscience
- Pharmacology
Background:
- The P2X7 receptor (P2X7R) is implicated in neuroinflammation and various neurological disorders.
- Developing selective P2X7R antagonists is crucial for therapeutic intervention.
Purpose of the Study:
- To synthesize novel polycyclic amides.
- To evaluate their lipophilicity and P2X7R antagonistic activity.
- To assess the selectivity of these compounds for the P2X7R over other neuroreceptors.
Main Methods:
- Synthesis of polycyclic amides (compounds 2 and 5-9).
- Lipophilicity profiling using reverse-phase High-Performance Liquid Chromatography (HPLC).
- In vitro testing on rat spinal cord microglia cells to assess P2X7R antagonism.
- Screening for binding affinity to other neuroreceptor subtypes.
Main Results:
- Successful synthesis of polycyclic amides 2 and 5-9.
- All synthesized compounds exhibited P2X7R antagonistic properties.
- Compounds demonstrated high selectivity for P2X7R, with minimal binding to other neuroreceptor subtypes.
Conclusions:
- The novel polycyclic amides are potent and selective P2X7R antagonists.
- These compounds represent promising candidates for further investigation in the context of P2X7R-mediated diseases.
- The study establishes a foundation for developing targeted therapeutics for neuroinflammatory conditions.
Related Concept Videos
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
01:12GPCR Desensitization
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...